Review

Effect of UGT polymorphisms on pharmacokinetics and adverse reactions of mycophenolic acid in kidney transplant patients

Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Jiangsu Province, Changzhou, 213000, China

Search for more papers by this author

Nan Hu

*Author for correspondence: Tel.: +86 051 968 870 870;

E-mail Address: hn_324@163.com

https://orcid.org/0000-0002-7505-5001

Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Jiangsu Province, Changzhou, 213000, China

Search for more papers by this author

Published Online:28 Sep 2021https://doi.org/10.2217/pgs-2021-0087

View article

Abstract

Mycophenolic acid (MPA) is a common immunosuppressive drug for kidney transplantation patients, and is characterized by a narrow therapeutic index and significant individual variability. UGTs are the main enzymes responsible for the metabolism of MPA. Although, many studies have focused on the relationship between UGT polymorphisms and pharmacokinetics and adverse reactions of MPA, the conclusion are controversial. We reviewed the relevant literature and summarized the significant influences of UGT polymorphisms, such as UGT1A8 (rs1042597, rs17863762), UGT1A9 (rs72551330, rs6714486, rs17868320, rs2741045, rs2741045) and UGT2B7 (rs7438135, rs7439366, rs7662029), on the pharmacokinetics of MPA and its metabolites and adverse reactions. The review provides a reference for guiding the individualized administration of MPA and reducing adverse reactions to MPA.

Keywords:

References

1. Dasgupta A. Therapeutic drug monitoring of mycophenolic acid. Adv. Clin. Chem. 76, 165–184 (2016).
Medline CASGoogle Scholar
2. Bentata Y. Mycophenolates: the latest modern and potent immunosuppressive drugs in adult kidney transplantation: what we should know about them? Artif. Organs 44(6), 561–576 (2020).
Medline CASGoogle Scholar
3. Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch. Toxicol. 88(7), 1351–1389 (2014).
Medline CASGoogle Scholar
4. Bumgardner GL, Roberts JP. New immunosuppressive agents. Gastroenterol. Clin. North Am. 22(2), 421–449 (1993).
Medline CASGoogle Scholar
5. Zhang J, Sun Z, Zhu Z et al. Pharmacokinetics of mycophenolate mofetil and development of limited sampling strategy in early kidney transplant recipients. Front. Pharmacol. 9, 908 (2018).
MedlineGoogle Scholar
6. Guo M, Wang ZJ, Yang HW et al. Influence of genetic polymorphisms on mycophenolic acid pharmacokinetics and patient outcomes in renal transplantation. Curr. Drug Metab. 19(14), 1199–1205 (2018).
Medline CASGoogle Scholar
7. Fujiyama N, Miura M, Kato S, Sone T, Isobe M, Satoh S. Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab. Dispos. 38(12), 2210–2217 (2010).
Medline CASGoogle Scholar
8. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin. Pharmacokinet. 46(1), 13–58 (2007).
Medline CASGoogle Scholar
9. Kuypers DRJ, Meur YL, Cantarovich M et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin. J. Am. Soc. Nephro. 5(2), 341–358 (2010).
CASGoogle Scholar
10. Klotsman M, Sathyan G, Anderson WH, Garden OA, Shivanand P. Mycophenolic acid in patients with immune-mediated inflammatory diseases: from humans to dogs. J. Vet. Pharmacol. Ther. 42(2), 127–138 (2019).
MedlineGoogle Scholar
11. Ling J, Shi J, Jiang Q, Jiao Z. Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil. Eur. J. Clin. Pharmacol. 71(1), 95–106 (2015).
Medline CASGoogle Scholar
12. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant. Proc. 28(2), 925–929 (1996).
Medline CASGoogle Scholar
13. Schütz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin. Chem. 45(3), 419–422 (1999).
Medline CASGoogle Scholar
14. Wieland E, Shipkova M, Schellhaas U et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin. Biochem. 33(2), 107–113 (2000).
Medline CASGoogle Scholar
15. Kuypers DR, Vanrenterghem Y, Squifflet JP et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther. Drug Monit. 25(5), 609–622 (2003).
Medline CASGoogle Scholar
16. Meech R, Hu DG, McKinnon RA et al. The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms. Physiol. Rev. 99(2), 1153–1222 (2019).
Medline CASGoogle Scholar
17. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab. Dispos. 33(1), 139–146 (2005).
Medline CASGoogle Scholar
18. Ramirez J, Ratain MJ, Innocenti F. Uridine 5′-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 6(4), 563–585 (2010).
CASGoogle Scholar
19. Innocenti F, Liu W, Fackenthal D et al. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet. Genomics 18(8), 683–697 (2008).
Medline CASGoogle Scholar
20. Barraclough KA, Lee KJ, Staatz CE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 11(3), 369–390 (2010).
CASGoogle Scholar
21. Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos. 32(8), 775–778 (2004).
Medline CASGoogle Scholar
22. Mackenzie PI. Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther. Drug Monit. 22(1), 10–13 (2000).
Medline CASGoogle Scholar
23. Mojarrabi B, Mackenzie PI. Characterization of two UDP glucuronosyltransferases that are predominantly expressed in human colon. Biochem. Biophys. Res. Commun. 247(3), 704–709 (1998).
Medline CASGoogle Scholar
24. Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE. PharmGKB summary: mycophenolic acid pathway. Pharmacogenet. Genomics 24(1), 73–79 (2014).
Medline CASGoogle Scholar
25. Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab. Dispos. 34(9), 1539–1545 (2006).
Medline CASGoogle Scholar
26. Basit A, Neradugomma NK, Wolford C et al. Characterization of differential tissue abundance of major non-CYP enzymes in human. Mol. Pharm. 17(11), 4114–4124 (2020).
Medline CASGoogle Scholar
27. Mackenzie PI, Bock KW, Burchell B et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics 15(10), 677–685 (2005).
Medline CASGoogle Scholar
28. Miura M, Kagaya H, Satoh S et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther. Drug Monit. 30(5), 559–564 (2008).
Medline CASGoogle Scholar
29. Miura M, Niioka T, Kato S et al. Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. Ther. Drug Monit. 33(3), 295–302 (2011).
Medline CASGoogle Scholar
30. Basu NK, Kole L, Kubota S, Owens IS. Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab. Dispos. 32(7), 768–773 (2004).
Medline CASGoogle Scholar
31. Xie XC, Li J, Wang HY et al. Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients. Acta Pharmacol. Sin. 36(5), 644–650 (2015).
Medline CASGoogle Scholar
32. Woillard JB, Rerolle JP, Picard N et al. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. Br. J. Clin. Pharmacol. 69(6), 675–683 (2010).
Medline CASGoogle Scholar
33. Zhou Z, Lu Y, Song G et al. In vitro study on influences of UGT1A8 gene polymorphisms on mycophenolate mofetil metabolism. Exp. Clin. Transplant. 16(4), 466–472 (2018).
MedlineGoogle Scholar
34. Johnson LA, Oetting WS, Basu S, Prausa S, Matas A, Jacobson PA. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur. J. Clin. Pharmacol. 64(11), 1047–1056 (2008).
Medline CASGoogle Scholar
35. van Schaik RH, van Agteren M, de Fijter JW et al. UGT1A9 -275T >A/-2152C >T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin. Pharmacol. Ther. 86(3), 319–327 (2009).
Medline CASGoogle Scholar
36. Picard N, Yee SW, Woillard JB et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin. Pharmacol. Ther. 87(1), 100–108 (2010).
Medline CASGoogle Scholar
37. Vu D, Tellez-Corrales E, Yang J et al. Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1alpha and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Transpl. Immunol. 29(1–4), 155–161 (2013).
Medline CASGoogle Scholar
38. Kagaya H, Inoue K, Miura M et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63(3), 279–288 (2007).
Medline CASGoogle Scholar
39. Geng F, Jiao Z, Dao YJ et al. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals. Clin. Chim. Acta 413(7–8), 683–690 (2012).
MedlineGoogle Scholar
40. Li LQ, Chen DN, Li CJ et al. Impact of UGT2B7 and ABCC2 genetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients. Pharmacogenomics 19(17), 1323–1334 (2018).
CASGoogle Scholar
41. Woillard JB, Picard N, Thierry A, Touchard G, Marquet P. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenet. Genomics 24(5), 256–262 (2014).
Medline CASGoogle Scholar
42. Varnell CD, Fukuda T, Kirby CL et al. Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: influence of genes and drugs. Pediatr. Transplant. 21(7), e13033 (2017).
Google Scholar
43. Kuypers DR, Claes K, Evenepoel P et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J. Clin. Pharmacol. 43(8), 866–880 (2003).
Medline CASGoogle Scholar
44. Zhao W, Fakhoury M, Deschenes G et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J. Clin. Pharmacol. 50(11), 1280–1291 (2010).
Medline CASGoogle Scholar
45. Betonico GN, Abbud-Filho M, Goloni-Bertollo EM et al. Influence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side effects in kidney transplant patients. Transplant. Proc. 40(3), 708–710 (2008).
Medline CASGoogle Scholar
46. Prausa SE, Fukuda T, Maseck D et al. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin. Pharmacol. Ther. 85(5), 495–500 (2009).
Medline CASGoogle Scholar
47. Boso V, Herrero MJ, Buso E et al. Genotype and allele frequencies of drug-metabolizing enzymes and drug transporter genes affecting immunosuppressants in the Spanish white population. Ther. Drug Monit. 36(2), 159–168 (2014).
Medline CASGoogle Scholar
48. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther. 78(4), 351–361 (2005).
Medline CASGoogle Scholar
49. Pazik J, Oldak M, Lewandowski Z et al. Recipient uridine 5′-diphospho-glucuronosyltransferase UGT1A9 c.98T >C variant determines transplanted kidney filtration rate. Transplant. Proc. 46(8), 2678–2682 (2014).
Medline CASGoogle Scholar
50. Michelon H, Konig J, Durrbach A et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 11(12), 1703–1713 (2010).
CASGoogle Scholar
51. Baldelli S, Merlini S, Perico N et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8(9), 1127–1141 (2007).
CASGoogle Scholar
52. Ruschel LR, Schmitt VM, Silva AB et al. Study on the association of UGT1A9 gene c.98T >C polymorphism and mycophenolic acid plasma levels in renal transplant patients. Genet. Mol. Res. 16(2), gmr16029598 (2017).
Google Scholar
53. Filler G, Alvarez-Elias AC, McIntyre C, Medeiros M. The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy. Pediatr. Nephrol. 32(1), 21–29 (2017).
MedlineGoogle Scholar
54. Mazidi T, Rouini MR, Ghahremani MH et al. Impact of UGT1A9 polymorphism on mycophenolic acid pharmacokinetic parameters in stable renal transplant patients. Iran. J. Pharm. Res. 12(3), 547–556 (2013).
Medline CASGoogle Scholar
55. Sanchez-Fructuoso AI, Maestro ML, Calvo N et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant. Proc. 41(6), 2313–2316 (2009).
Medline CASGoogle Scholar
56. Kuypers DR, de Jonge H, Naesens M et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin. Ther. 30(4), 673–683 (2008).
Medline CASGoogle Scholar
57. Ciliao HL, Camargo-Godoy R, Souza MF, Zanuto A, Delfino V, Colus I. Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil. Mutat. Res. Genet. Toxicol. Environ. Mutagen 836(Pt B), 97–102 (2018).
Medline CASGoogle Scholar
58. Billing H, Hocker B, Fichtner A et al. Single-nucleotide polymorphism of CYP3A5 impacts the exposure to tacrolimus in pediatric renal transplant recipients: a pharmacogenetic substudy of the TWIST trial. Ther. Drug Monit. 39(1), 21–28 (2017).
Medline CASGoogle Scholar
59. Ciliao HL, Camargo-Godoy R, de Souza MF et al. Association of UGT2B7, UGT1A9, ABCG2, and IL23R polymorphisms with rejection risk in kidney transplant patients. J. Toxicol. Environ. Health A 80(13–15), 661–671 (2017).
Medline CASGoogle Scholar
60. Girard H, Court MH, Bernard O et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14(8), 501–515 (2004).
Medline CASGoogle Scholar
61. Fukuda T, Goebel J, Cox S et al. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther. Drug Monit. 34(6), 671–679 (2012).
Medline CASGoogle Scholar
62. Girard H, Villeneuve L, Court MH et al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab. Dispos. 34(7), 1220–1228 (2006).
Medline CASGoogle Scholar
63. Ciftci HS, Demir E, Karadeniz MS et al. Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant. Ren. Fail. 40(1), 395–402 (2018).
Medline CASGoogle Scholar
64. Inoue K, Miura M, Satoh S et al. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther. Drug Monit. 29(3), 299–304 (2007).
Medline CASGoogle Scholar
65. Kagaya H, Niioka T, Saito M et al. Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. Xenobiotica 47(10), 916–922 (2017).
Medline CASGoogle Scholar
66. Zhang WX, Chen B, Jin Z et al. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica 38(11), 1422–1436 (2008).
Medline CASGoogle Scholar
67. Yamanaka H, Nakajima M, Katoh M et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14(5), 329–332 (2004).
Medline CASGoogle Scholar
68. Xiao C, Sun H, Deng G, Song G. Effect of SNP rs10187694 of UGT1A10 gene on metabolism of mycophenolate mofetil. Chin. J. Mod. Med. 27(12), 9–14 (2017).
Google Scholar
69. Pithukpakorn M, Tiwawanwong T, Lalerd Y et al. Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms. Pharmgenomics Pers. Med. 7, 379–385 (2014).
MedlineGoogle Scholar
70. Djebli N, Picard N, Rerolle JP, Le Meur Y, Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet. Genomics 17(5), 321–330 (2007).
Medline CASGoogle Scholar
71. van Agteren M, Armstrong VW, van Schaik RH et al. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G >A gene polymorphism. Ther. Drug Monit. 30(4), 439–444 (2008).
Medline CASGoogle Scholar
72. Song G, Deng G, Wang Y et al. Effect of SNP rs7439366 in UGT2B7 on MMF metabolism. J. Med. Res. 44(11), 22–25 (2015).
CASGoogle Scholar
73. Pazik J, Oldak M, Lewandowski Z et al. Uridine diphosphate glucuronosyltransferase 2B7 variant p.His268Tyr as a predictor of kidney allograft early acute rejection. Transplant. Proc. 45(4), 1516–1519 (2013).
Medline CASGoogle Scholar
74. Yang JW, Lee PH, Hutchinson IV, Pravica V, Shah T, Min DI. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther. Drug Monit. 31(5), 542–548 (2009).
Medline CASGoogle Scholar
75. Duguay Y, Baar C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin. Pharmacol. Ther. 75(3), 223–233 (2004).
Medline CASGoogle Scholar
76. Yu ZC, Zhou PJ, Wang XH et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients. Acta Pharmacol. Sin. 38(11), 1566–1579 (2017).
Medline CASGoogle Scholar
77. Dupuis R, Yuen A, Innocenti F. The influence of UGT polymorphisms as biomarkers in solid organ transplantation. Clin. Chim. Acta 413(17–18), 1318–1325 (2012).
Medline CASGoogle Scholar
78. Hesselink DA, van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin. Pharmacol. Ther. 78(4), 317–321 (2005).
Medline CASGoogle Scholar
79. Satoh S, Tada H, Murakami M et al. Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 82(4), 486–493 (2006).
Medline CASGoogle Scholar
80. Genvigir F, Nishikawa AM, Felipe CR et al. Influence of ABCC2, CYP2C8, and CYP2J2 polymorphisms on tacrolimus and mycophenolate sodium-based treatment in Brazilian kidney transplant recipients. Pharmacotherapy 37(5), 535–545 (2017).
Medline CASGoogle Scholar
81. Varnell CD, Fukuda T, Kirby CL et al. Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: influence of genes and drugs. Pediatr. Transplant. 21(7), e13033 (2017).
Google Scholar
82. Levesque E, Benoit-Biancamano MO, Delage R, Couture F, Guillemette C. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Pharmacogenomics 9(7), 869–879 (2008).
CASGoogle Scholar
83. Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333(18), 1171–1175 (1995).
Medline CASGoogle Scholar
84. Evans WE, McLeod HL. Pharmacogenomics – drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538–549 (2003).
Medline CASGoogle Scholar

Vol. 22, No. 15

Metrics

Downloaded 314 times

History

Received 30 June 2021

Accepted 31 August 2021

Published online 28 September 2021

Published in print October 2021

Information

Keywords

Financial & competing interests disclosure

This work was supported by the Changzhou HighLevel Medical Talents Training Project (no. 2016CZBJ010). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download